A RESTROSPECTIVE NON-INTERVENTIONAL STUDY AMONG PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS SWITCHING TO FINGOLIMOD OR TO OTHER DISEASE MODIFYING THERAPIES

被引：0

作者：

Medin, J. ^{[1
]}

Haddad, P. ^{[2
]}

Ricart, J. ^{[3
]}

Lara, N. ^{[4
]}

Pedros, M. ^{[4
]}

Bizouard, G. ^{[5
]}

Loefroth, E. ^{[1
]}

机构：

[1] Novartis Pharma AG, Basel, Switzerland

[2] Novartis Pharmaceut Canada Inc, Dorval, PQ, Canada

[3] Novartis Farmaceut SA, Barcelona, Spain

[4] IMS Hlth, Barcelona, Spain

[5] IMS Hlth RWE, Boulogne Billancourt, France

来源：

VALUE IN HEALTH | 2016年 / 19卷 / 07期

关键词：

D O I：

10.1016/j.jval.2016.09.465

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PND12

引用

页码：A427 / A427

页数：1

共 50 条

[21] Audit of patients switching disease-modifying therapies for the treatment of multiple sclerosis
Embrey, NH
Woolmore, JA
Hawkins, CP
MULTIPLE SCLEROSIS, 2005, 11 : S159 - S159
[22] Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis
Stefan Braune
M. Lang
A. Bergmann
Journal of Neurology, 2016, 263 : 327 - 333
[23] Efficacy of fingolimod is superior to injectable disease modifying therapies in second-line therapy of relapsing remitting multiple sclerosis
Braune, Stefan
Lang, M.
Bergmann, A.
JOURNAL OF NEUROLOGY, 2016, 263 (02) : 327 - 333
[24] RELAPSE RATES AND SYMPTOM MANAGEMENT AMONG PATIENTS RECEIVING NATALIZUMAB AND OTHER DISEASE-MODIFYING THERAPIES FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS
Lee, L.
Pike, J.
Kendter, J.
Campagnolo, D.
Jones, E.
Naoshy, S.
VALUE IN HEALTH, 2016, 19 (07) : A427 - A427
[25] Disease-modifying therapies in relapsing-remitting multiple sclerosis
Gonzalez-Andrade, Fabricio
Luis Alcaraz-Alvarez, Jose
NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2010, 6 : 365 - 373
[26] The Shifting Landscape of Disease-Modifying Therapies for Relapsing Multiple Sclerosis
Burton, Jodie M.
Freedman, Mark S.
JOURNAL OF NEURO-OPHTHALMOLOGY, 2018, 38 (02) : 210 - 216
[27] Reasons for switching to fingolimod in patients relapsing-remitting multiple sclerosis in France: the ESGILE study
Tourbah, Ayman
Papeix, Caroline
Tourniaire, Patricia
Rerat, Karin
Meite, Mohamed
Durand, Barbara
Lamy, Fabienne
Chouette, Isabelle
Mekies, Claude
Aboab, Jennyfer
Al Khedr, Abdullatif
Carpentier, Amer Al Najjar
Androdias, Geraldine
Benrabah, Rabah
Biotti, Damien
Bohotin, Valentin
Bonnan, Mickael
Bonnet, Cecilia
Boulesteix, Jean Marc
Brassat, David
Busson, Philippe
Camu, William
Castelnovo, Giovanni
Chapuis, Stephane
Clavelou, Pierre
Convers, Philippe
Coustans, Marc
Creange, Alain
Delassaux, Sebastien
Diot, Eric
Djerdi, Madjid
Drouet, Thomas
Delalande, Sophie Dufour
Pottier, Corinne Dupel
Ferriby, Didier
Gaida, Philippe
Gal, Guillaume
Giraud, Pierric
Guilloton, Laurent
Hascar, Tijani
Heinzlef, Olivier
Rouaud, Violaine Jaffrenou
Jager, Alain
Kubler, Christophe
Le Coz, Patrick
Frenay, Christine Lebrun
Maillart, Elisabeth
Vioud, Paris Marcel Maillet
Malkoun, Imad
Manchon, Eric
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 46
[28] Assessing Preferences for Attributes of Disease-Modifying Therapies among Patients with Relapsing-Form of Multiple Sclerosis: A Discrete Choice Study
Ye, Xiaolan
Kantor, Daniel
Barbato, Luigi
Wakeford, Craig
Yang, Min
Macaulay, Dendy
Marshall, Thomas
NEUROLOGY, 2017, 88
[29] Effect of early switch to fingolimod from other oral therapies in patients with relapsing-remitting multiple sclerosis
Ziemssen, T.
Silva, D.
Medin, J.
Cornelissen, C.
Ringwald, K.
Cohan, S.
MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 404 - 405
[30] Health Outcomes in Patients With Relapsing Multiple Sclerosis Switching From Fingolimod to Ozanimod
Hersh, C. M.
Paul, D.
Wang, C.
Poul, R.
Khaychuk, V.
Thorpe, A.
Chaudhry, B.
Reardon, J.
Conway, D. S.
MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 198 - 199

← 1 2 3 4 5 →